AI assistant
CONMED Corp — Director's Dealing 2022
Feb 4, 2022
31971_dirs_2022-02-04_30e7c78d-46de-4982-bc57-2fcbeffd5fd8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CONMED Corp (CNMD)
CIK: 0000816956
Period of Report: 2022-02-02
Reporting Person: CONCANNON BRIAN (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-02-02 | Common Stock | S | 2027 | $135.09 | Disposed | 13400 | Direct |
| 2022-02-02 | Common Stock | S | 4200 | $136.96 | Disposed | 9200 | Direct |
| 2022-02-02 | Common Stock | S | 200 | $137.91 | Disposed | 9000 | Direct |
| 2022-02-02 | Common Stock | M | 2549 | $69.03 | Acquired | 11549 | Direct |
| 2022-02-02 | Common Stock | S | 2549 | $135.08 | Disposed | 9000 | Direct |
| 2022-02-02 | Common Stock | M | 2165 | $79.94 | Acquired | 11165 | Direct |
| 2022-02-02 | Common Stock | S | 2165 | $135.08 | Disposed | 9000 | Direct |
| 2022-02-02 | Common Stock | M | 1843 | $73.94 | Acquired | 10843 | Direct |
| 2022-02-02 | Common Stock | S | 1843 | $135.06 | Disposed | 9000 | Direct |
| 2022-02-02 | Common Stock | M | 1000 | $33.43 | Acquired | 10000 | Direct |
| 2022-02-02 | Common Stock | F | 241 | $139.03 | Disposed | 9759 | Direct |
| 2022-02-02 | Common Stock | M | 1000 | $39.64 | Acquired | 10759 | Direct |
| 2022-02-02 | Common Stock | F | 286 | $139.03 | Disposed | 10473 | Direct |
| 2022-02-02 | Common Stock | M | 1000 | $55.70 | Acquired | 11473 | Direct |
| 2022-02-02 | Common Stock | F | 401 | $139.03 | Disposed | 11072 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-02 | Options To Purchase Common Stock | $69.03 | M | 2549 | Disposed | 2028-06-01 | Common Stock (2549) | Direct |
| 2022-02-02 | Options To Purchase Common Stock | $79.94 | M | 2165 | Disposed | 2029-06-03 | Common Stock (2165) | Direct |
| 2022-02-02 | Options To Purchase Common Stock | $73.94 | M | 1843 | Disposed | 2030-06-01 | Common Stock (1843) | Direct |
| 2022-02-02 | Sars (Stock Appreciation Rights) | $33.43 | M | 1000 | Disposed | 2023-07-26 | Common Stock (1000) | Direct |
| 2022-02-02 | Sars (Stock Appreciation Rights) | $39.64 | M | 1000 | Disposed | 2024-09-11 | Common Stock (1000) | Direct |
| 2022-02-02 | Sars (Stock Appreciation Rights) | $55.70 | M | 1000 | Disposed | 2025-06-01 | Common Stock (1000) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.83. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.29 to $137.06. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.88 to $137.94. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.82. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.84. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.12. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
F7: The incentive stock options ("ISOs") were granted under the Company's 2016 Amended and Restated Non-Employee Director Equity Compensation Plan and generally vest 100% after a one year period.
F8: The stock options were granted under the Company's 2020 Amended and Restated Non-Employee Director Equity Compensation Plan and generally vest 100% after a one year period.
F9: The stock appreciation rights ("SARs") were granted under the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the SARs generally vesting 100% after a one year period.
F10: The stock appreciation rights ("SARs") were granted under the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the SARs generally vesting upon completion of the term of service.